The Business of Biofabrication

The headline is liver tissue in space. The more important development may be happening on Earth.

Pluristyx, the Wake Forest Institute for Regenerative Medicine, Innovian Space and the RegenMed Development Organization are working together to develop a standardized manufacturing workflow for clinical-grade hepatocytes derived from induced pluripotent stem cells.

The immediate objective is to create a repeatable supply of liver cells that can support implantable liver constructs and potentially bridge-to-transplantation therapies.

A bridge-to-transplant product would not need to permanently replace every function of the liver. Instead, it could provide temporary support for patients with acute or advanced liver failure while they wait for a donor organ.

That is still an extraordinarily difficult clinical and manufacturing challenge. But it represents a narrower objective than building a complete, permanent replacement liver.

The collaboration divides the problem across several specialized organizations.

Pluristyx will provide clinical-grade iPSC technologies, cell-banking workflows and hepatocyte differentiation protocols aligned with its regulatory and Drug Master File strategy.

Wake Forest will focus on developing and evaluating tissue-engineered liver constructs.

The RegenMed Development Organization will support commercialization, reimbursement and regulatory strategy.

Innovian Space will connect the program with NASA’s In-Space Production Applications initiative and explore whether microgravity could eventually provide advantages for manufacturing or maturing liver tissue.

The consortium is targeting process optimization and initial validation by December 2026, followed by progress toward InSPA Phase 2 readiness in 2027.

The resulting hepatocytes will be evaluated for important liver functions including albumin production, bilirubin clearance, urea synthesis, coagulation-factor secretion and broader metabolic activity.

The Business Is Bigger Than One Liver Product

The interesting part of the announcement is not simply that another group is trying to engineer liver tissue.

It is the structure of the collaboration.

Biofabrication is beginning to develop something closer to a real manufacturing supply chain.

Producing a therapeutic tissue construct requires much more than successfully printing or assembling cells in a laboratory.

A developer needs:

clinical-grade starting cells,

reproducible differentiation,

manufacturing processes,

release specifications,

quality-control systems,

regulatory documentation,

and sufficient manufacturing capacity to produce the same product repeatedly.

Variability at any one of those stages can prevent a promising academic technology from becoming a commercial product.

This is where Pluristyx’s position becomes particularly interesting.

Rather than betting entirely on one therapeutic, the company is positioning itself near the beginning of the biofabrication value chain.

Its platform includes clinical-grade iPSC lines, cell engineering, safety technologies, immune-evasion technologies and manufacturing support.

If multiple companies eventually develop liver tissues, organoids, cell therapies or other products requiring clinically compatible hepatocytes, Pluristyx does not necessarily have to own the winning therapeutic.

It can potentially provide part of the infrastructure used to build it.

Biofabrication Is Starting to Unbundle

Early biofabrication companies often tried to own nearly the entire technology stack.

Cells.

Biomaterials.

Printers.

Manufacturing processes.

Tissue constructs.

And ultimately the therapeutic itself.

That model can work, but it also requires one company to solve several extremely difficult problems simultaneously.

The Pluristyx collaboration suggests another possible direction.

Specialized companies and organizations may increasingly own different layers of the manufacturing stack.

Pluristyx provides standardized biological inputs and cell-engineering infrastructure.

Wake Forest develops the tissue application.

ReMDO helps move the technology toward commercialization.

Innovian explores a specialized manufacturing environment.

Instead of asking only:

Who can print a liver?

the industry may increasingly ask:

Who owns each critical layer required to manufacture one reproducibly?

That distinction matters.

In mature industries, enormous businesses often emerge not only around the final product, but around the infrastructure required by many different products.

Biofabrication may eventually work the same way.

What About Manufacturing in Space?

The space component is understandably the most attention-grabbing part of the program.

Microgravity may provide advantages for certain forms of tissue assembly, maturation or cell behavior that are difficult to reproduce under normal gravitational conditions.

But demonstrating a biological advantage is only the first step.

For orbital manufacturing to become commercially meaningful, that advantage must ultimately justify the additional complexity and cost of producing biological products in space.

Launch costs, specialized equipment, production throughput, sample return, regulatory oversight and supply-chain reliability all become part of the economics.

The key commercial question is therefore not simply whether liver cells behave differently in microgravity.

It is:

Do they become sufficiently better that customers will pay the logistical premium required to manufacture them there?

NASA’s In-Space Production Applications program is designed around exactly this challenge: identifying products that can gain meaningful advantages in low-Earth orbit and eventually support sustainable commercial demand.

For hepatocytes, that remains an open question.

The More Important Near-Term Opportunity

The standardized hepatocyte workflow itself may therefore be more commercially important than the space component.

A validated, clinically compatible supply of liver cells could potentially support multiple applications.

Those could include implantable liver constructs, organoids, drug-discovery models, extracorporeal liver-support systems and eventually larger engineered tissues.

If that happens, the valuable asset is not simply one liver product.

It is the manufacturing system underneath many of them.

That is a broader pattern beginning to emerge across biofabrication.

The field is moving beyond demonstrations that tissues can be printed or assembled.

The next question is whether those tissues can be manufactured repeatedly, under controlled conditions, using standardized inputs and processes that regulators and clinicians can trust.

The headline may be liver tissue in space.

The larger story is the formation of a biofabrication manufacturing stack.

Space may be the experiment. Standardized biological manufacturing may be the business.